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Dear Editor,
We read the interesting study by Szymczak et al. (1) 
regarding  the  safety  and  effectiveness  of  a  blind  per-
cutaneous liver biopsy, where they concluded that the 
failure rate and the risk of complications are low if indi-
cations and contraindications are carefully considered. 
Moreover, these authors emphasize how important it is 
that biopsies are performed by skilled and experienced 
operators. This study raises controversy, however, as al-
though a liver biopsy is reasonably safe, it is still an inva-
sive procedure and it is unclear as to whether the histol-
ogy results affect the management of patients with liver 
disease. In addition, the increasing availability of non-
invasive techniques for staging hepatic fibrosis, together 
with new and advanced radiological, immunological, 
virological and molecular genetic tests, may undermine 
the future role of liver biopsy in clinical practice. 
It has recently been reported (Björnsson E, et al., 2011) 
that patients with typical laboratory features of auto-
immune hepatitis (AIH) rarely need a liver biopsy for 
their diagnosis and moreover, that most patients with 
hallmark features of AIH are likely to have a compatible 
liver histology. In the few patients with atypical histol-
ogy, these findings also have little impact on their clini-
cal management. Thus, a biopsy might be unnecessary in 
patients who meet the clinical criteria for AIH. This state-
ment might be considered controversial, particularly in 
those patients who are difficult to categorize due to an 
atypical clinical presentation. Diagnosing drug-induced 
liver injury relies primarily on careful history taking; 
nevertheless, we had the opportunity to study two illus-
trative cases of patients with acute flares of severe hepa-
titis that underwent ultrasound-guided liver biopsy for 
diagnostic characterization. In these patients the histo-
logical findings played a decisive role in determining the 
specific therapeutic intervention required, which subse-
quently led to a remission of the acute disease (2, 3). 
It is generally accepted that a liver biopsy in patients 
with chronic hepatitis B is indicated in order to pre-
scribe antiviral therapy, this is usually when serum ALT 
is very low and in suspected cases of advanced fibrosis 
(> F2) who are at risk of developing cirrhosis. Concern-
ing chronic hepatitis C, a liver biopsy was previously 
recommended prior to commencing therapy in order to 
determine whether treatment was warranted and to as-
sess disease prognosis (grading and staging). In current 295 Hepat Mon. 2012;12(4)
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clinical practice this postulation has been revised and 
now the main role of a biopsy is the objective quantifi-
cation of liver fibrosis into meaningful clinical groups, 
in particular, those at risk of progression to cirrhosis. 
Additionally, histological analysis in chronic viral hepa-
titis could tentatively include molecular analysis such as 
in situ hybridization or polymerase chain reaction used 
to detect occult viral infections, identification of prema-
lignant lesions or in the context of clinical and research 
protocols (4, 5). 
In summary, Szymczak et al. (1) confirmed the safety 
and success of a blind liver biopsy and reference an ex-
tensive number of studies by experienced authors. In 
current medical practice, however, the importance of 
this invasive procedure is based on a  well designed clini-
cal rationale and knowledge of its precise indications.  It 
can therefore be stated, that a decision on each individ-
ual case must be made in order to obtain helpful infor-
mation for therapeutic interventions, and to establish an 
adequate follow-up protocol for prognostic control.
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